Catheter Precision Inc. (VTAK)

Catheter Precision (NASDAQ: VTAK) is seeking stockholder approval for several proposals, including reincorporating from Delaware to Nevada to reduce franchise tax costs and enhance director protections. The company also proposes an amendment to its Series J preferred stock conversion terms, which could increase the maximum issuable common shares to approximately 41 million, and an increase of 5 million shares to its 2023 Equity Incentive Plan, alongside a one-time repricing of underwater stock options. These proposals aim to provide financial flexibility and align incentives but carry significant potential for dilution to existing shareholders.

A group of investment entities and individuals, including C/M Capital Master Fund, LP, WVP Emerging Manager Onshore Fund LLC, C/M Capital Partners, LP, Thomas Walsh, and Jonathan Juchno, has reported a collective beneficial ownership of 9.99% of Catheter Precision, Inc.'s common stock (VTAK). This stake, totaling 1,597,328 shares, includes 159,574 shares issuable upon conversion of convertible preferred stock. The reporting persons share voting and dispositive power, though Messrs. Walsh and Juchno disclaim beneficial ownership of shares held by the funds.

Flyte, a subsidiary of Catheter Precision, Inc. (NYSE: VTAK), announced that it has surpassed 10,000 registered consumer accounts on its WebApp, with new account creation accelerating significantly in August. Despite this milestone, VTAK shares dipped by 2.8%. The company highlighted robust growth in new accounts, with nearly a quarter of its total accounts created in the last 30 days.

Flyte, a private aviation platform, reported a 170% increase in new account creations in the first 17 days of August compared to the same period in July, adding 1,830 new users. This surge, which has already surpassed July's total, indicates strong traction for the company, effective customer acquisition strategies, and expanded market reach across 174 airports in 19 states. The company leverages valuable first-party data and strategic partnerships to optimize marketing and drive revenue growth.

Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), announced it has surpassed 10,000 consumer accounts on its private aviation WebApp, with significant growth acceleration in August 2026. From August 1–17, Flyte added 1,830 accounts, a 170% increase compared to the same period in July. The company attributes this rapid growth to its technology, strategic partnerships, and direct customer engagement, highlighting the potential for data-driven expansion across 174 airports in 19 states.